SCHEMBL397004

SCHEMBL397004

CC(N)CC(N)CC(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRP O00591 2/20 0.46
GABRD O14764 2/20 0.46
GABRA1 P14867 2/20 0.46
GABRB1 P18505 2/20 0.46
GABRG2 P18507 2/20 0.46
GABRB3 P28472 2/20 0.46
GABRA5 P31644 2/20 0.46
GABRA3 P34903 2/20 0.46
GABRA2 P47869 2/20 0.46
GABRB2 P47870 2/20 0.46
GABRA4 P48169 2/20 0.46
GABRE P78334 2/20 0.46
GABRA6 Q16445 2/20 0.46
GABRG1 Q8N1C3 2/20 0.46
GABRG3 Q99928 2/20 0.46
GABRQ Q9UN88 2/20 0.46
CACNA2D1 P54289 2/20 0.45
CACNB3 P54284 1/20 0.45
CACNA1C Q13936 1/20 0.45
PGR P06401 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL60920 1.00 GABRP (0.46) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL6061178 0.88 BHMT (0.44) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL2377939 0.85 CACNA2D1 (0.56) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL2763515 0.85 CACNA2D1 (0.56) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL4996654 0.85 GABRP (0.46) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL288273 0.85 CACNA2D1 (0.56) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL8510926 0.83 CACNA2D1 (0.43) GABRPGABRDGABRA1GABRB1GABRG2
Hydrochloric Acid SCHEMBL10977884 0.83 CACNA2D1 (0.54) GABRPGABRDGABRA1GABRB1GABRG2
Hydrochloric Acid SCHEMBL10977886 0.83 CACNA2D1 (0.54) GABRPGABRDGABRA1GABRB1GABRG2
Acetic Acid SCHEMBL2853697 0.81 CACNA2D1 (0.52) GABRPGABRDGABRA1GABRB1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11688519-B2 Method and system for monitoring the gut health of an individual TATA CONSULTANCY SERVICES LIMITED (IN) 2023-06-27 US claimed
US-11452746-B2 Bacteria-comprising compositions and methods of using the same for treating and/or preventing gastrointestinal, metabolic and/or other diseases WAGENINGEN UNIVERSITEIT (NL) 2022-09-27 US claimed
US-11426436-B2 Bacteria-comprising compositions and methods of using the same for treating and/or preventing gastrointestinal, metabolic and/or other diseases WAGENINGEN UNIVERSITEIT (NL) 2022-08-30 US claimed
CN-106119113-B Organisms for the production of 1, 3-butanediol 基因组股份公司 2026-05-12 CN disclosed
US-20240269197-A1 INSULIN-SENSITIZING AGENT AND BUTYRATE-PRODUCING BACTERIUM Caelus Lifesciences IP B.V. (NL) 2024-08-15 US disclosed
EP-4346857-A1 INSULIN-SENSITIZING AGENT AND BUTYRATE-PRODUCING BACTERIUM Caelus Pharmaceuticals B.V. (NL) 2024-04-10 EP disclosed
EP-4324882-A2 BINDERS Knauf Insulation SPRL (BE) 2024-02-21 EP disclosed
EP-3146010-B1 BINDERS KNAUF INSULATION INC (US) 2023-12-13 EP disclosed
EP-3865569-B1 ORGANISMS FOR THE PRODUCTION OF 1,3-BUTANEDIOL GENOMATICA INC (US) 2023-10-04 EP disclosed
US-20230159979-A1 TRANSDUCERS, NANOPARTICLE TRANSDUCER DEVICES AND SYSTEMS, AND RELATED METHODS OF USE UNIVERSITY OF WASHINGTON (US) 2023-05-25 US disclosed
CN-113755462-B Beta-amino acid dehydrogenase mutant and application thereof 中国科学院天津工业生物技术研究所 2023-04-18 CN disclosed
WO-2008073918-A1 NON-STANDARD AMINO ACID CONJUGATES OF AMPHETAMINE AND PROCESSES FOR MAKING AND USING THE SAME KEMPHARM, INC. (US) 2008-06-19 WO disclosed
US-20080139653-A1 Non-standard amino acid conjugates of amphetamine and processes for making and using the same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-06-12 US disclosed
US-20050118665-A1 Methods for conducting assays for enzyme activity on protein microarrays PROTOMETRIX, INC. 2005-06-02 US disclosed
CN-1083460-C Method for producing crosslinked polyaspartic acid resin MITSUI CHEMICALS LNC (JP) 2002-04-24 CN disclosed
US-6346569-B1 DISPERSING FEED POLYSUCCINIMIDE WITH DISPERSANT, REACTING DISPERSED POLYSUCCINIMIDE WITH CROSS-LINKING AGENT MITSUI CHEMICALS, INC. (JP) 2002-02-12 US disclosed
US-6072024-A Production process of cross-linked polyaspartic acid resin MITSUI CHEMICALS, INC. (JP) 2000-06-06 US disclosed
EP-0885970-A1 METHOD FOR ASSAYING AMMONIA AND COMPOSITION THEREFOR Asahi Kasei Kogyo Kabushiki Kaisha (JP) 1998-12-23 EP disclosed
EP-0866084-A2 Production process of cross-linked polyaspartic acid resin Mitsui Chemicals, Inc. (JP) 1998-09-23 EP disclosed
EP-0308983-A2 NMR imaging with Mn(II) coordination compositions SALUTAR, INC. (US) 1989-03-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240269197-A1 INSULIN-SENSITIZING AGENT AND BUTYRATE-PRODUCING BACTERIUM CPT1A, GPR119, IRS1 GABRP 349/4885GABRD 591/4885GABRA1 298/4885
US-20080139653-A1 Non-standard amino acid conjugates of amphetamine and processes for making and using the same SLC6A3, AADAT, SLC6A2 GABRP 433/4885GABRD 582/4885GABRA1 462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.